| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Revenue | $15.06B | -6.2% |
| Cost of Revenue | $11.91B | -9.7% |
| R&D Expense | $49.0M | -15.5% |
| SG&A Expense | $2.59B | -6.6% |
| Interest Expense | $100.0M | -18.0% |
| Pre-tax Income | $435.0M | +358.9% |
| Income Tax | $184.0M | +7.0% |
| Net Income | $252.0M | +174.1% |
| EPS (Basic) | $1.09 |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.79B | +15.0% |
| Accounts Receivable | $1.34B | -15.9% |
| Current Assets | $4.59B | -3.3% |
| Total Assets | $10.45B | -1.3% |
| Current Liabilities | $4.30B | -6.3% |
| Long-term Debt | $2.90B | +0.0% |
| Total Liabilities | $9.12B | -3.7% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $942.0M | +107.5% |
| Investing Cash Flow | -$404.0M | +26.9% |
| Financing Cash Flow | -$286.0M | -68.2% |
| +173.6% |
| EPS (Diluted) | $1.05 | +170.9% |
| Stockholders' Equity |
| $1.22B |
| +20.1% |